Bettina has more than 15 years of international experience in the pharmaceutical industry as well as 10 years of experience as a tenured professor at the Faculty of Pharmacy at Université Laval. Prior to assuming her current role as President and CEO of Ontario Genomics, Bettina served as Vice-President of NSERC’s Research Partnerships Directorate. She has also held a variety of leadership positions at Pfizer Canada. She is known for pioneering novel public-private partnership models, and breaking down barriers between federal, provincial and private sector stakeholders. Bettina holds a B.Sc. in pharmacy and a Doctor of Pharmacy from the University of Kentucky, U.S. and an EMBA in Healthcare from the UBC

Mr. Adams is Board Chair of the Best Medicines Coalition, Co-founder, President & CEO of Canadian PKU and Allied Disorders non-profit and Co-Founder and Trustee of the Global Association for PKU. He is a former Chair of the Canadian Organization for Rare Disorders.

Mr. Adams is a graduate of York University; worked as a reporter for The Globe and Mail; chief of staff to a Cabinet Minister in Ontario; elected three times to Toronto City Council, serving as Budget Chief and Acting Mayor; and served as a trustee of Canada’s largest hospital, the University Health Network

Eric began his career by co-founding and selling a software company to Optio Software, helping guide Optio to a successful IPO by expanding into the healthcare market and launching its European headquarters. During his career, Eric has been helping software and professional services firms such as PwC all over the world in shifting the paradigm of their business development culture, resulting in new contracts worth $100+ million.  He is a frequent speaker and works closely with hospitals, pharma companies and research institutes on patient recruitment programs.

In 1999, Ray was appointed Assistant Professor in the Department of Biochemistry at McMaster University , where he started new projects on polyglutamine diseases, focusing on Huntington’s Disease. In 2001, Ray won the CIHR “New Scientist” award and his group is now supported by operating grants from Canada and the United States. In 2010, he was promoted to full Professor in Biochemistry and Biomedical Sciences.

Professor Truant is Chair of the Scientific Advisory board of the Huntington Society of Canada since 2007.  Dr. Truant is a recipient of the 2012 Queen Elizabeth II Diamond Jubilee Medal and the 2014 Michael Wright Community Leadership Award.

The Truant lab is in an academic setting, but highly collaborative with pharmaceutical industry and biotech partners, as well as clinical collaborators, Dr. Mark Guttman at the Centre for Movement Disorders in Toronto and Toronto Western Hospital and the University of Toronto, as well as Dr. Mark Tarnopolsky at McMaster’s Neuromuscular Disease Clinic.  Dr. Truant is on the Scientific Advisory Board of Mitokinin LLC, a biotech firm dedicated to the development of small molecules drug therapy to restore the phosphorylation of mutant Huntingtin and thus treat Huntington’s disease.

Drew Memmott is currently the Senior Vice President for Research Administration at Dana-Farber Cancer Institute and Associate Director for Administration for the Dana-Farber/Harvard Cancer Center, a National Cancer Institute (NCI) designated Comprehensive Cancer Center comprised of 5 Harvard-affiliated teaching hospitals and 2 Harvard biomedical schools. He is the senior administrative leader for all aspects of research at DFCI and the DF/HCC consortium. In his role as SVP he is responsible for oversight of the research administrative infrastructure (including grant and contract management, core facilities, laboratory operations, and the animal resource facility) and clinical research operations (including clinical trials administration and operations, Institutional Review Board, protocol review approval and activation, and clinical trials financial management). In his role as Associate Director for Administration for DF/HCC he oversees the administration of the DF/HCC Cancer Center Support Grant and its associated operational requirements including administration, shared resources, and clinical research support.
Prior to DFCI Drew held a number of senior leadership roles at Mayo Clinic. He was the Associate Director for Administration for the Mayo Clinic Comprehensive Cancer Center, an NCI designated national cancer center with operations in three geographic regions. Additionally, Drew also served as a Director of Research Administration at Columbia University Medical Center.
Drew is an active member of the Cancer Center Administrator’s Forum (CCAF), an organization of NCI designated Cancer Center Administrators; the Association of American Cancer Institutes (AACI); an External Advisory Board Member for several NCI designated cancer centers; and the National Council of University Research Administrators (NCURA) where he has served in multiple committee leadership roles.

Jennifer Chan was appointed Vice President, Policy and External Affairs, at Merck Canada Inc. as of June 1, 2014 and is responsible for the company’s team of government relations and public affairs specialists.  Prior to this role, she held the position of Vice President, Policy and Communications at Merck Canada since December 2011.

A native of Montreal, Jennifer began her career in academic research before joining Schering-Plough in 1993 as a Clinical Research Associate. Since then, she has worked in various areas of the business, primarily in Regulatory Affairs, Specialty Services and Medical Affairs. She was Director of Regulatory Affairs, for Schering Plough at the time of the merger with Merck in 2009.

Jennifer is a member of the Board of Directors of the Institute of Health Economics in Alberta, as well as the Quebec Consortium for Drug Discovery and the Quebec Network for Personalized Health Care. She is a member of the board of Life Sciences Ontario and has served as a Merck for Mothers ambassador in Canada since the program was launched in 2011. Jennifer holds a Bachelor of Science degree in physiology and a Master of Science degree in pharmacology and therapeutics, both from McGill University in Montreal. She completed the last year of her master’s degree at Baylor College of Medicine in Houston, Texas.

As Healthcare Industry Lead for Microsoft Canada, Peter Jones is responsible for developing the strategy vision of modern healthcare for the Canadian marketplace. Working closely with the Microsoft Worldwide Healthcare team, Peter is deeply enriched in the best practices of healthcare digital transformation that is being practiced by healthcare industry leaders around the globe. Peter’s mandate is to help clients improve their clinical and operational performance by leveraging Microsoft solutions for healthcare data and records management, advanced analytics, and big data, while remaining compliant. Peter joined Microsoft nearly 20 years ago and has been focused on the healthcare industry for over 10 years. He is actively involved in a number Health Informatics groups such as COACH, CHIEF (Advisor), and is an active ITAC Health board member.

Charles Weijer is Professor and Canada Research Chair in Bioethics at the Rotman Institute of Philosophy at Western University in London, Canada. He is the leading expert on the ethics of randomized controlled trials. In 2008, Charles founded the Rotman Institute of Philosophy, which is dedicated to fostering collaboration between the humanities and the sciences, and served as the Institute’s first director. In 2014, he received Western’s Hellmuth Prize for Achievement in Research, and, in 2016, he was elected to the Royal Society of Canada

Dr. Frank Naus is the Chief Operating Officer of Allphase Clinical Research Inc., a Canadian CRO headquartered in Ottawa, Ontario. Frank earned his Doctorate in Business Administration from Walden University and has an MBA from Wilfrid Laurier University and MSc and BSc degrees in Applied Health Sciences from the University of Waterloo. Frank started his career in the pharmaceutical and clinical research industry. Prior to joining Allphase, he was Vice President Research at Hamilton Health Sciences.